Edition:
United States

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

1.20USD
25 Apr 2018
Change (% chg)

$-0.11 (-8.40%)
Prev Close
$1.31
Open
$1.30
Day's High
$1.30
Day's Low
$1.20
Volume
866
Avg. Vol
19,698
52-wk High
$6.87
52-wk Low
$1.07

Chart for

About

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer. The Company's product pipeline includes Therapeutic (MVT-5873),... (more)
No analyst recommendations are available for .

Overall

Beta: 1.51
Market Cap(Mil.): $11.02
Shares Outstanding(Mil.): 8.96
Dividend: --
Yield (%): --

Financials

  MBVX.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -4.32 -- --
ROI: -408.44 -0.73 12.97
ROE: -1,472.23 -2.77 14.84

BRIEF-MabVax Therapeutics Regains Compliance With NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement

* MABVAX THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT Source text for Eikon: Further company coverage:

Mar 06 2018

BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075

* MABVAX THERAPEUTICS REPORTS POSITIVE SAFETY RESULTS FROM INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS

Feb 28 2018

BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16

* MABVAX THERAPEUTICS SCHEDULES PREVIOUSLY ANNOUNCED 1-FOR-3 REVERSE STOCK SPLIT TO REGAIN COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT

Feb 15 2018

BRIEF-Barry Honig Reports 4.99 Pct Stake In MabVax Therapeutics

* BARRY HONIG REPORTS 4.99 PERCENT STAKE IN MABVAX THERAPEUTICS HOLDINGS INC AS OF FEBRUARY 12, 2018 - SEC FILING‍​

Feb 13 2018

BRIEF-John Stetson Reports 4.99 Pct Stake In Mabvax Therapeutics Holdings

* JOHN STETSON REPORTS 4.99 PERCENT STAKE IN MABVAX THERAPEUTICS HOLDINGS INC AS OF FEBRUARY 12 - SEC FILING Source text: (http://bit.ly/2EoGXsh) Further company coverage:

Feb 12 2018

BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873

* MABVAX THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM EXPANDED COHORT IN PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN PANCREATIC CANCER

Feb 12 2018

BRIEF-Mabvax Therapeutics Holdings Provides Business Strategy Update

* MABVAX THERAPEUTICS HOLDINGS, INC. PROVIDES BUSINESS STRATEGY UPDATE

Jan 16 2018

BRIEF-MabVax Therapeutics Files For Resale Of 16.6 Mln Shares Of Co's Common Stock

* MABVAX THERAPEUTICS HOLDINGS INC FILES FOR RESALE OF 16.6 MILLION SHARES OF CO'S COMMON STOCK BY CERTAIN OF CO'S STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2of4wAj) Further company coverage:

Dec 15 2017

BRIEF-MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug

* MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS

Dec 13 2017

BRIEF-Mabvax to present three posters at AACR-NCI-EORTC Int'l conference

* Mabvax therapeutics to present three posters at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics Source text for Eikon: Further company coverage:

Oct 26 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF74.74 -1.02
Roche Holding Ltd. (ROG.S) CHF216.80 -2.40
Roche Holding Ltd. (RO.S) CHF221.80 -2.00
Merck & Co., Inc. (MRK.N) $59.36 -0.73
Bayer AG (BAYGn.DE) €96.94 -1.03
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €66.33 +0.91
Eli Lilly And Co (LLY.N) $82.26 +2.17
Abbott Laboratories (ABT.N) $58.39 +0.08
Amgen, Inc. (AMGN.OQ) $172.73 +0.79

Earnings vs. Estimates